CN1391482A - 新型治疗方法 - Google Patents

新型治疗方法 Download PDF

Info

Publication number: CN1391482A
Authority: CN; China
Prior art keywords: hepatitis; medicated bag; vaccine; antiviral agent; lamivudine
Prior art date: 1999-01-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN99816471A

Other languages

English (en)

Chinese (zh)

Inventor

G·F·阿特金森

R·J·波恩

P·G·范德帕佩利雷

M·A·C·维藤多夫

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Biologicals SA

Original Assignee

SmithKline Beecham Biologicals SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-12

Filing date

1999-12-21

Publication date

2003-01-15

1999-12-21 Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA

2003-01-15 Publication of CN1391482A publication Critical patent/CN1391482A/zh

Status Pending legal-status Critical Current

Links

238000002560 therapeutic procedure Methods 0.000 title description 2
229960005486 vaccine Drugs 0.000 claims abstract description 31
208000002672 hepatitis B Diseases 0.000 claims abstract description 24
239000000427 antigen Substances 0.000 claims abstract description 23
102000036639 antigens Human genes 0.000 claims abstract description 23
108091007433 antigens Proteins 0.000 claims abstract description 23
239000003443 antiviral agent Substances 0.000 claims abstract description 23
241000700721 Hepatitis B virus Species 0.000 claims abstract description 14
238000011282 treatment Methods 0.000 claims abstract description 13
229960001627 lamivudine Drugs 0.000 claims description 34
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 34
238000000034 method Methods 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 15
239000002671 adjuvant Substances 0.000 claims description 14
239000002777 nucleoside Substances 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 10
150000003833 nucleoside derivatives Chemical class 0.000 claims description 9
JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical group N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 8
229960004396 famciclovir Drugs 0.000 claims description 8
GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 8
229960001179 penciclovir Drugs 0.000 claims description 8
241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 7
150000001413 amino acids Chemical class 0.000 claims description 6
239000007764 o/w emulsion Substances 0.000 claims description 6
230000000840 anti-viral effect Effects 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 5
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims description 5
229940124736 hepatitis-B vaccine Drugs 0.000 claims description 5
125000003729 nucleotide group Chemical group 0.000 claims description 5
206010070834 Sensitisation Diseases 0.000 claims description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
230000008313 sensitization Effects 0.000 claims description 4
239000011732 tocopherol Substances 0.000 claims description 4
229960001295 tocopherol Drugs 0.000 claims description 4
229930003799 tocopherol Natural products 0.000 claims description 4
235000010384 tocopherol Nutrition 0.000 claims description 4
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 claims description 2
108091034117 Oligonucleotide Proteins 0.000 claims description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 2
229960001997 adefovir Drugs 0.000 claims description 2
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
235000012000 cholesterol Nutrition 0.000 claims description 2
229960002963 ganciclovir Drugs 0.000 claims description 2
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
229950005339 lobucavir Drugs 0.000 claims description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
229920000053 polysorbate 80 Polymers 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
229960000329 ribavirin Drugs 0.000 claims description 2
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
229940031439 squalene Drugs 0.000 claims description 2
229960003636 vidarabine Drugs 0.000 claims description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
229910021502 aluminium hydroxide Inorganic materials 0.000 claims 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
239000004480 active ingredient Substances 0.000 abstract 2
229940124872 Hepatitis B virus vaccine Drugs 0.000 abstract 1
229940127073 nucleoside analogue Drugs 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
241000282472 Canis lupus familiaris Species 0.000 description 19
238000002360 preparation method Methods 0.000 description 11
230000036470 plasma concentration Effects 0.000 description 9
230000009885 systemic effect Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
238000011160 research Methods 0.000 description 6
238000007796 conventional method Methods 0.000 description 5
229940035032 monophosphoryl lipid a Drugs 0.000 description 5
238000005070 sampling Methods 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000725618 Duck hepatitis B virus Species 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000003203 everyday effect Effects 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
238000012856 packing Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
238000010241 blood sampling Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000011246 composite particle Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
-1 hydroxypropyl Chemical group 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002245 particle Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000004044 response Effects 0.000 description 2
HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical class C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
SFLGIMGLWCVAHP-UHFFFAOYSA-N 5h-oxathiole Chemical compound C1OSC=C1 SFLGIMGLWCVAHP-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000000419 Chronic Hepatitis B Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
239000011627 DL-alpha-tocopherol Substances 0.000 description 1
241000792859 Enema Species 0.000 description 1
229940124884 Engerix-B Drugs 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
108700032491 Hepatitis virus nucleocapsid Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000283923 Marmota monax Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
241000283925 Spermophilus Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
101710137302 Surface antigen S Proteins 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000004519 grease Substances 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000009413 insulation Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002505 iron Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000005497 microtitration Methods 0.000 description 1
125000003835 nucleoside group Chemical class 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940100691 oral capsule Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000004575 stone Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CN99816471A 1999-01-12 1999-12-21 新型治疗方法 Pending CN1391482A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9900630		1999-01-12
GB9900630.6		1999-01-12

Publications (1)

Publication Number	Publication Date
CN1391482A true CN1391482A (zh)	2003-01-15

Family

ID=10845878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN99816471A Pending CN1391482A (zh)	1999-01-12	1999-12-21	新型治疗方法

Country Status (19)

Country	Link
EP (1)	EP1140163A2 (fr)
JP (1)	JP2002534438A (fr)
KR (1)	KR20010090011A (fr)
CN (1)	CN1391482A (fr)
AR (1)	AR022250A1 (fr)
AU (1)	AU760574B2 (fr)
BR (1)	BR9916893A (fr)
CA (1)	CA2359110A1 (fr)
CO (1)	CO5241355A1 (fr)
CZ (1)	CZ20012544A3 (fr)
HK (1)	HK1041434A1 (fr)
HU (1)	HUP0105070A2 (fr)
IL (1)	IL144186A0 (fr)
NO (1)	NO20013337L (fr)
NZ (1)	NZ512890A (fr)
PL (1)	PL349347A1 (fr)
TR (1)	TR200102024T2 (fr)
WO (1)	WO2000041463A2 (fr)
ZA (1)	ZA200105690B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100443117C (zh) *	2003-05-13	2008-12-17	深圳康泰生物制品股份有限公司	一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
WO2020134682A1 (fr) *	2018-12-24	2020-07-02	南京远大赛威信生物医药有限公司	Préparation pharmaceutique pour le traitement de l'hépatite b, procédé de préparation s'y rapportant et utilisation associée

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999061056A2 (fr)	1998-05-22	1999-12-02	Loeb Health Research Institute At The Ottawa Hospital	Methodes et produits permettant d'induire une immunite au niveau des muqueuses
CN1560078B (zh)	1998-07-31	2011-06-22	株式会社国际癌症免疫研究所	基于癌抑制基因wt1的产物的癌抗原
CA2440303C (fr)	2001-03-22	2013-03-19	Haruo Sugiyama	Peptide modifie wt1
US8735357B2 (en)	2001-09-28	2014-05-27	International Institute Of Cancer Immunology, Inc.	Method of inducing antigen-specific T cells
JPWO2003028758A1 (ja) *	2001-09-28	2005-01-13	治夫杉山	抗原特異的ｔ細胞の誘導方法
MY131488A (en) *	2002-04-08	2007-08-30	Bristol Myers Squibb Co	Low dose liquid entecavir formulations and use
PT2241325E (pt)	2002-10-29	2012-04-12	Coley Pharm Gmbh	Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
AU2003300919A1 (en)	2002-12-11	2004-06-30	Coley Pharmaceutical Gmbh	5' cpg nucleic acids and methods of use
US8541167B2 (en)	2004-06-03	2013-09-24	Saint Louis University	Methods and compositions for vaccination
AR065504A1 (es) *	2007-02-28	2009-06-10	Ct Ingenieria Genetica Biotech	Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
EP4321173A1 (fr) *	2021-04-07	2024-02-14	Denka Company Limited	Activateur d'activité d'adjuvant et composition d'adjuvant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2109921T3 (es) *	1989-07-25	1998-02-01	Smithkline Beecham Biolog	Nuevos antigenos y procedimientos para su preparacion.
EP1064025B1 (fr) *	1998-03-09	2006-09-13	GlaxoSmithKline Biologicals S.A.	Compositions de vaccins combines

1999
- 1999-12-21 PL PL99349347A patent/PL349347A1/xx not_active Application Discontinuation
- 1999-12-21 KR KR1020017008833A patent/KR20010090011A/ko not_active Application Discontinuation
- 1999-12-21 CN CN99816471A patent/CN1391482A/zh active Pending
- 1999-12-21 CZ CZ20012544A patent/CZ20012544A3/cs unknown
- 1999-12-21 AU AU21009/00A patent/AU760574B2/en not_active Ceased
- 1999-12-21 TR TR2001/02024T patent/TR200102024T2/xx unknown
- 1999-12-21 EP EP99965531A patent/EP1140163A2/fr not_active Withdrawn
- 1999-12-21 HU HU0105070A patent/HUP0105070A2/hu unknown
- 1999-12-21 IL IL14418699A patent/IL144186A0/xx unknown
- 1999-12-21 JP JP2000593088A patent/JP2002534438A/ja active Pending
- 1999-12-21 WO PCT/EP1999/010295 patent/WO2000041463A2/fr not_active Application Discontinuation
- 1999-12-21 CA CA002359110A patent/CA2359110A1/fr not_active Abandoned
- 1999-12-21 BR BR9916893-6A patent/BR9916893A/pt not_active IP Right Cessation
- 1999-12-21 NZ NZ512890A patent/NZ512890A/en unknown
2000
- 2000-01-11 AR ARP000100107A patent/AR022250A1/es not_active Application Discontinuation
- 2000-01-12 CO CO00001261A patent/CO5241355A1/es not_active Application Discontinuation
2001
- 2001-07-05 NO NO20013337A patent/NO20013337L/no not_active Application Discontinuation
- 2001-07-11 ZA ZA200105690A patent/ZA200105690B/xx unknown
2002
- 2002-02-19 HK HK02101211.9A patent/HK1041434A1/zh unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100443117C (zh) *	2003-05-13	2008-12-17	深圳康泰生物制品股份有限公司	一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
WO2020134682A1 (fr) *	2018-12-24	2020-07-02	南京远大赛威信生物医药有限公司	Préparation pharmaceutique pour le traitement de l'hépatite b, procédé de préparation s'y rapportant et utilisation associée

Also Published As

Publication number	Publication date
KR20010090011A (ko)	2001-10-17
TR200102024T2 (tr)	2001-12-21
EP1140163A2 (fr)	2001-10-10
CZ20012544A3 (cs)	2002-01-16
AR022250A1 (es)	2002-09-04
JP2002534438A (ja)	2002-10-15
HK1041434A1 (zh)	2002-07-12
NO20013337L (no)	2001-08-17
WO2000041463A3 (fr)	2000-11-09
PL349347A1 (en)	2002-07-15
IL144186A0 (en)	2002-05-23
ZA200105690B (en)	2002-09-25
NO20013337D0 (no)	2001-07-05
WO2000041463A2 (fr)	2000-07-20
AU2100900A (en)	2000-08-01
CA2359110A1 (fr)	2000-07-20
CO5241355A1 (es)	2003-01-31
NZ512890A (en)	2003-09-26
BR9916893A (pt)	2001-11-20
HUP0105070A2 (hu)	2002-04-29
AU760574B2 (en)	2003-05-15

Legal Events

Date	Code	Title
2003-01-15	C06	Publication
2003-01-15	PB01	Publication
2003-04-02	C10	Entry into substantive examination
2003-04-02	SE01	Entry into force of request for substantive examination
2004-10-06	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2004-10-06	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CN1391482A (zh)	2003-01-15	新型治疗方法
US10052378B2 (en)	2018-08-21	Pharmaceutical compositions comprising CpG oligonucleotides
JP3802348B2 (ja)	2006-07-26	タンパク質薬物または抗原を含む、親油性微細粒子およびそれを含む剤形
JPH11501018A (ja)	1999-01-26	Ｂ型肝炎ワクチン
WO2014139359A1 (fr)	2014-09-18	Vaccin contre l'hépatite b
CN102949717A (zh)	2013-03-06	一种含poly I:C佐剂的新型乙肝疫苗制剂
JP2010209118A (ja)	2010-09-24	新規組成物
CN117897487A (zh)	2024-04-16	人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
CN101309931A (zh)	2008-11-19	包含截短的hbc核心蛋白和基于皂苷的佐剂的疫苗
US20040191214A1 (en)	2004-09-30	Nucleoside vaccine adjuvants
CN116568309A (zh)	2023-08-08	用于预防或治疗慢性乙型肝炎的、包含作为活性成分的口服抗病毒药物和含脂肽和聚(i：c)佐剂的治疗性疫苗的药物组合物、药物组合制剂和组合制剂试剂盒
KR20210151047A (ko)	2021-12-13	B형 간염 치료를 위한 면역원성 조성물
CN1404875A (zh)	2003-03-26	一种乙型肝炎疫苗
TW202034950A (zh)	2020-10-01	用於治療b型肝炎的藥物製劑及其製備方法和用途
JP2021503460A (ja)	2021-02-12	Ｂ型肝炎ウイルス感染症の治療におけるシアノバクテリアバイオマスの使用
CN1069544C (zh)	2001-08-15	人用阿片类毒品戒毒疫苗
MXPA01007112A (en)	2002-03-05	Novel treatment
Park et al.	2007	Immune responses of mice to influenza subunit vaccine in combination with CIA07 as an adjuvant
CN1401389A (zh)	2003-03-12	新的乙型肝炎疫苗制剂
Fazeli et al.	2008	Aluminum phosphate shows more adjuvanticity than Aluminum hydroxide in recombinant hepatitis–B vaccine formulation
JP2016132636A (ja)	2016-07-25	人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤

CN1391482A - 新型治疗方法 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=10845878

Family Applications (1)

Country Status (19)

Cited By (2)

Families Citing this family (11)

Family Cites Families (2)

Cited By (2)

Also Published As

Similar Documents

Legal Events